A Study of XY03-EA Tablets in the Treatment of Acute Ischemic Stroke

PHASE2/PHASE3Enrolling by invitationINTERVENTIONAL
Enrollment

360

Participants

Timeline

Start Date

December 15, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

December 31, 2025

Conditions
Stroke, Ischemic
Interventions
DRUG

XY03-EA

"The sample size was 360 patients, and 72patients were treated with XY03-EA 150 mg, 300mgA group ,300mgBgroup,450mg and placebo respectively. The 150mg group took two tablets of placebo and one tablet of XY03-EA once, three times a day. For 90 days The 300mg A-group took one tablet of placebo and two tablets of XY03-EA once,three times a day. For 90 days The 300mg B-group took one tablet of placebo and two tablets of XY03-EA once,three times a day. Use continuously for 14 days.Placebo is used for 15-90 days.~The 450mg group took three tablets of XY03-EA once,three times a day. For 90 days.~The placebo group took three tablets of placebo once ,three times a day.For 90 days."

Trial Locations (1)

050035

Shijiazhuang Yiling Pharmaceutical Co., Ltd, Shijiazhuang

All Listed Sponsors
lead

Shijiazhuang Yiling Pharmaceutical Co. Ltd

INDUSTRY